A Phase 3 interventional study of Ravulizumab and Placebo in Thrombotic Microangiopathy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 66 sites in 17 countries. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab plus best supportive care or matching placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1, and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week follow-up period.
52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.
This study's enrollment of 148 is above the median of 40 across 24 interventional studies indexed under Thrombotic Microangiopathies.
Browse Thrombotic Microangiopathies studies →Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC). In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC).
Biological: Ravulizumab · Other: Best supportive care
In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.
Other: Placebo · Other: Best supportive care
Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
Also known as: Ultomiris, ALXN1210
Matching placebo
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment Period
Event-free survival was defined as the time from randomization until the first of the 2 following events: death (due to any cause) and clinical worsening up through Week 26. Clinical worsening was defined as meeting 2 or more of the following criteria: doubling of serum creatinine from baseline or new requirement of dialysis; increase in lactate dehydrogenase (LDH) \>25% compared to baseline; reduction in platelets of \>25% compared to baseline; reduction in hemoglobin \>10% compared to baseline; increased requirement for platelets or red blood cells at any time. The criteria for clinical worsening had to be confirmed by 2 independent samples collected at least 8 hours apart (ideally 24 hours apart).
Time frame: Up to Week 26
Stage 2: Overall Survival
The Kaplan-Meier method was used to measure overall survival estimate. For Day 100 and Week 26, overall survival was calculated from randomization to death (due to any cause), up to Day 100/Week 26. Participants who survived were censored at the earliest of an additional hematopoietic stem cell transplant (HSCT), Day 100/Week 26, or their last known date alive. For Week 52, overall survival was calculated from randomization to death (due to any cause), up to Week 52. Participants who survived were censored at the earlier of an additional HSCT, or their last known date alive up to Week 52.
Time frame: Up to Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)
Stage 2: Non-relapse Mortality
Cumulative incidence for each group was estimated using a competing risks model. Non-relapse mortality was defined as a participant's death due to any cause during the study, with the exception of death due to underlying disease (malignant or non-malignant reason for HSCT) progression or relapse.
Time frame: Baseline through Day 100 (Treatment Period), Week 26 (Treatment Period), and Week 52 (Follow-up Period)
Stage 2: Mean Number of Thrombotic Microangiopathy (TMA) Response Criteria Met During the 26-week Treatment Period
The TMA response parameters included: platelet response, normalization of LDH and absence of schistocytes, and renal response. A participant could have met 0, 1, 2, or 3 TMA response criteria during the 26-week Treatment Period. If the participants met more than 1 TMA response criterion, the number of responses overlapping for at least 24 hours was counted. Least squares mean determined from a general linear model adjusted by acute GVHD status and geographic region, assuming normal data distribution.
Time frame: Baseline through Week 26
Stage 2: Percentage of Participants With Hematologic Response During the 26-week Treatment Period
Clinical laboratory assessments were performed according to the protocol and assessed against the following predetermined criteria for hematologic response: if baseline platelet count was ≤50000/cubic millimeter (mm\^3), then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count had to be \>50000/mm\^3, then there must be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes (defined as ≤1% or a result of "none", per the International Council for Standardization in Hematology recommendations for schistocyte counting).
Time frame: Baseline through Week 26
Stage 2: Change From Baseline in the Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 52
The eGFR was calculated based on serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula. Serum creatinine was collected according to the protocol. Data reported as milliliters/minute/1.73 square meters (mL/min/1.73 m\^2).
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Percentage of Participants With TMA Response During the 26-week Treatment Period
The criteria for TMA response included a hematological response and a renal response. Hematological Response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Participants must have met each of the response criteria, with each parameter meeting the requirements at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. A participant could meet 0, 1, 2, or 3 TMA response criteria during the treatment period. If the participant met more than 1 TMA response criterion, the number of responses overlapping for at least 24 hours was counted.
Time frame: Baseline through Week 26
Stage 2: Cumulative Proportion of Participants Who Experienced a Complete TMA Response During the 26-week Treatment Period
Cumulative proportion of participants who experienced a complete TMA response was estimated using a competing risks model based on the time (days) to complete TMA response. Time to complete TMA response was defined as the days from randomization to the first day during the 26-week Treatment Period on which a participant met all criteria for a complete TMA response. The date of complete TMA response was defined as the first date on which all individual response criteria were met simultaneously.
Time frame: Baseline through Week 26
Stage 2: Cumulative Proportion of Participants Experiencing Each Individual Component of TMA During the 26-week Treatment Period
Cumulative proportion of participants experiencing individual TMA components included those for platelet count, LDH, and protein/creatinine ratio. For platelet count: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days. For LDH: normalization of LDH and absence of schistocytes. For protein/creatinine ratio: at least 50% reduction of proteinuria from baseline.
Time frame: Baseline through Week 26
Stage 2: Cumulative Proportion of Participants Experiencing a Hematologic Response During the 26-week Treatment Period
Clinical laboratory assessments were performed according to the protocol and assessed against the following predetermined criteria for hematologic response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days.
Time frame: Baseline through Week 26
Stage 2: Percentage of Participants With Hemoglobin Response During the 26-week Treatment Period
Hemoglobin response was defined as the ability to maintain hemoglobin ≥10 grams/deciliter (g/dL) without any support. The criterion had to be met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between, and without any support during the prior 7 days.
Time frame: Baseline through Week 26
Stage 2: Percentage of Participants With Platelet Response During the 26-week Treatment Period
Platelet response was defined as: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days. The criteria had to be met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.
Time frame: Baseline through Week 26
Stage 2: Percentage of Participants With Partial Response During the 26-week Treatment Period
The criteria for TMA response included a hematological response and a renal response. Hematological response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Partial response occurred when the participant met ≥1, but not all, criteria for TMA response.
Time frame: Baseline through Week 26
Stage 2: Percentage of Participants With Loss of TMA Response During the 26-week Treatment Period
For participants that met the criteria for TMA response during the 26-week Treatment Period, loss of TMA response was defined as when the participant failed to meet the criteria for 1 or more components of TMA response at a subsequent visit during the 26-week Treatment Period. At least 1 parameter must have failed to meet the response criteria at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.
Time frame: Baseline through Week 26
Stage 2: Duration of TMA Response
This analysis includes data for each participant after achieving TMA response under the composite strategy through Weeks 26 and 52. The criteria for TMA response included a hematological response and a renal response. Time was calculated as the number of days from TMA response under the composite strategy to first loss of response or intercurrent event in the treatment period, or TMA relapse in the follow-up period. Participants must have met each of the response criteria, with each parameter meeting the requirements at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. Participants with TMA response who did not experience these events were censored at their end of study date. The estimate is calculated based on the Kaplan-Meier method. Non-responders were counted as an event with a duration of zero day.
Time frame: Baseline through Week 52
Stage 2: Change From Baseline in Haptoglobin at Week 26 and Week 52
Protocol-specified blood samples were taken for the analysis of haptoglobin in plasma at designated time points. Results are reported as grams/liter (g/L).
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Change From Baseline in Platelets at Week 26 and Week 52
Protocol-specified blood samples were taken for the analyses of platelets in plasma at designated time points.
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Change From Baseline in LDH at Week 26 and Week 52
Protocol-specified blood samples were taken for the analyses of LDH in plasma at designated time points. Results are reported as units/liter (U/L).
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Change From Baseline in Hemoglobin at Week 26 and Week 52
Protocol-specified blood samples were taken for the analyses of hemoglobin in plasma at designated time points.
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Percentage of Participants With Modified TMA Response During the 26-week Treatment Period
The modified criteria for TMA response included a hematological response and a renal response. Hematological Response: if baseline platelet count ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if baseline platelet count \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; at least 50% reduction of LDH from baseline and absence of schistocytes or normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Participants must have met each response criterion, with each parameter meeting the requirement at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.
Time frame: Baseline through Week 26
Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Renal System Through Week 26 and Week 52
Renal dysfunction was defined as doubling of serum creatinine from baseline or requirement of dialysis. Requirements for dialysis included: at the baseline visit, if there was any dialysis within 5 days prior to the first dose of study treatment; at the post-baseline visit, if there was any dialysis within 5 days prior to the visit. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Cardiopulmonary System Through Week 26 and Week 52
Cardiopulmonary dysfunction was defined as the presence of cardiopulmonary symptoms (excluding hypertension) or use of any mechanical ventilation. Cardiopulmonary symptoms included, but were not limited to, pleural effusion, pulmonary edema, pericardial effusion, and serositis. The presence of cardiopulmonary symptoms at baseline and post-baseline visits were assessed and recorded on the electronic case report form (eCRF). Use of any ventilatory or respiratory support, including mechanical ventilation, was reported on the participant's Nonpharmacologic Therapies and Procedures eCRF page. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Central Nervous System Through Week 26 and Week 52
Central nervous system dysfunction was defined as confirmed posterior reversible encephalopathy syndrome, or any signs of headache, confusion, visual loss, or seizures at baseline and post-baseline visits, as recorded on the eCRF. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Change From Baseline in Number of Participants With TMA-associated Organ Dysfunction in the Gastrointestinal System Through Week 26 and Week 52
Gastrointestinal dysfunction was defined as presence of signs and symptoms of gastrointestinal involvement at baseline and post-baseline visits, including diarrhea, vomiting, pain, and bleeding as recorded on the eCRF. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.
Time frame: Baseline, Week 26 (Treatment Period), Week 52 (Follow-up Period)
Stage 2: Percentage of Participants With TMA Relapse
For participants that met the criteria for TMA response during the 26-week Treatment Period, TMA relapse was defined as evidence of worsening hematologic and renal dysfunction due to TMA during the post-treatment Follow-up Period and required treatment intervention, as determined by the investigator.
Time frame: Baseline through Week 52
This study included 2 periods, each 26 weeks long: Treatment Period; Follow-up Period.
| Milestone | Ravulizumab: Stage 1 | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|---|
| Started | 20 | 64 | 62 |
| Received at least 1 dose of study drug | 20 | 63 | 62 |
| Full analysis set | 0 | 64 | 62 |
| Rescue ravulizumab: stage 2 | 0 | 0 | 10 |
| Completed | 6 | 34 | 24 |
| Not completed | 14 | 30 | 38 |
| Withdrew: Early discontinuation by participant | 0 | 0 | 1 |
| Withdrew: Disease progression | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 5 |
| Withdrew: Physician decision | 1 | 0 | 5 |
| Withdrew: Death | 8 | 27 | 23 |
| Withdrew: Adverse event | 4 | 0 | 2 |
| Milestone | Ravulizumab: Stage 1 | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|---|
| Started | 6 | 34 | 24 |
| Completed | 4 | 26 | 21 |
| Not completed | 2 | 8 | 3 |
| Withdrew: Other than specified | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Death | 1 | 6 | 1 |
Event-free survival was defined as the time from randomization until the first of the 2 following events: death (due to any cause) and clinical worsening up through Week 26. Clinical worsening was defined as meeting 2 or more of the following criteria: doubling of serum creatinine from baseline or new requirement of dialysis; increase in lactate dehydrogenase (LDH) \>25% compared to baseline; reduction in platelets of \>25% compared to baseline; reduction in hemoglobin \>10% compared to baseline; increased requirement for platelets or red blood cells at any time. The criteria for clinical worsening had to be confirmed by 2 independent samples collected at least 8 hours apart (ideally 24 hours apart).
| proportion of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment Period | 0.557 (0.427 to 0.669) | 0.475 (0.343 to 0.595) |
The Kaplan-Meier method was used to measure overall survival estimate. For Day 100 and Week 26, overall survival was calculated from randomization to death (due to any cause), up to Day 100/Week 26. Participants who survived were censored at the earliest of an additional hematopoietic stem cell transplant (HSCT), Day 100/Week 26, or their last known date alive. For Week 52, overall survival was calculated from randomization to death (due to any cause), up to Week 52. Participants who survived were censored at the earlier of an additional HSCT, or their last known date alive up to Week 52.
| proportion of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Day 100 | 0.589 (0.458 to 0.698) | 0.632 (0.497 to 0.740) |
| Week 26 | 0.573 (0.442 to 0.684) | 0.490 (0.357 to 0.610) |
| Week 52 | 0.458 (0.332 to 0.576) | 0.453 (0.322 to 0.575) |
Cumulative incidence for each group was estimated using a competing risks model. Non-relapse mortality was defined as a participant's death due to any cause during the study, with the exception of death due to underlying disease (malignant or non-malignant reason for HSCT) progression or relapse.
| proportion of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Day 100 | 0.395 (0.274 to 0.514) | 0.300 (0.189 to 0.419) |
| Week 26 | 0.411 (0.288 to 0.530) | 0.389 (0.264 to 0.512) |
| Week 52 | 0.509 (0.378 to 0.626) | 0.407 (0.280 to 0.531) |
The TMA response parameters included: platelet response, normalization of LDH and absence of schistocytes, and renal response. A participant could have met 0, 1, 2, or 3 TMA response criteria during the 26-week Treatment Period. If the participants met more than 1 TMA response criterion, the number of responses overlapping for at least 24 hours was counted. Least squares mean determined from a general linear model adjusted by acute GVHD status and geographic region, assuming normal data distribution.
| response criteria | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Mean Number of Thrombotic Microangiopathy (TMA) Response Criteria Met During the 26-week Treatment Period | 0.95 ± 0.172 | 0.80 ± 0.172 |
Clinical laboratory assessments were performed according to the protocol and assessed against the following predetermined criteria for hematologic response: if baseline platelet count was ≤50000/cubic millimeter (mm\^3), then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count had to be \>50000/mm\^3, then there must be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes (defined as ≤1% or a result of "none", per the International Council for Standardization in Hematology recommendations for schistocyte counting).
| percentage of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Percentage of Participants With Hematologic Response During the 26-week Treatment Period | 25.0 (15.0 to 37.4) | 17.7 (9.2 to 29.5) |
The eGFR was calculated based on serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula. Serum creatinine was collected according to the protocol. Data reported as milliliters/minute/1.73 square meters (mL/min/1.73 m\^2).
| mL/min/1.73 m^2 | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26 | -0.80 ± 27.920 | -2.95 ± 17.305 |
| Week 52 | -2.60 ± 30.218 | -8.85 ± 16.898 |
The criteria for TMA response included a hematological response and a renal response. Hematological Response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Participants must have met each of the response criteria, with each parameter meeting the requirements at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. A participant could meet 0, 1, 2, or 3 TMA response criteria during the treatment period. If the participant met more than 1 TMA response criterion, the number of responses overlapping for at least 24 hours was counted.
| percentage of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Percentage of Participants With TMA Response During the 26-week Treatment Period | 18.8 (10.1 to 30.5) | 14.5 (6.9 to 25.8) |
Cumulative proportion of participants who experienced a complete TMA response was estimated using a competing risks model based on the time (days) to complete TMA response. Time to complete TMA response was defined as the days from randomization to the first day during the 26-week Treatment Period on which a participant met all criteria for a complete TMA response. The date of complete TMA response was defined as the first date on which all individual response criteria were met simultaneously.
| proportion of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Cumulative Proportion of Participants Who Experienced a Complete TMA Response During the 26-week Treatment Period | 0.194 (0.105 to 0.301) | 0.151 (0.072 to 0.255) |
Cumulative proportion of participants experiencing individual TMA components included those for platelet count, LDH, and protein/creatinine ratio. For platelet count: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days. For LDH: normalization of LDH and absence of schistocytes. For protein/creatinine ratio: at least 50% reduction of proteinuria from baseline.
| proportion of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Platelet Count | 0.403 (0.278 to 0.525) | 0.274 (0.169 to 0.390) |
| LDH | 0.365 (0.247 to 0.484) | 0.290 (0.182 to 0.407) |
| Protein/Creatinine Ratio | 0.481 (0.351 to 0.600) | 0.419 (0.294 to 0.539) |
Clinical laboratory assessments were performed according to the protocol and assessed against the following predetermined criteria for hematologic response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days.
| proportion of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Cumulative Proportion of Participants Experiencing a Hematologic Response During the 26-week Treatment Period | 0.257 (0.155 to 0.372) | 0.181 (0.095 to 0.289) |
Hemoglobin response was defined as the ability to maintain hemoglobin ≥10 grams/deciliter (g/dL) without any support. The criterion had to be met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between, and without any support during the prior 7 days.
| percentage of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Percentage of Participants With Hemoglobin Response During the 26-week Treatment Period | 26.6 (16.3 to 39.1) | 12.9 (5.7 to 23.9) |
Platelet response was defined as: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days. The criteria had to be met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.
| percentage of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Percentage of Participants With Platelet Response During the 26-week Treatment Period | 39.1 (27.1 to 52.1) | 27.4 (16.9 to 40.2) |
The criteria for TMA response included a hematological response and a renal response. Hematological response: if baseline platelet count was ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if the baseline platelet count was \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Partial response occurred when the participant met ≥1, but not all, criteria for TMA response.
| percentage of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Percentage of Participants With Partial Response During the 26-week Treatment Period | 37.5 (25.7 to 50.5) | 40.3 (28.1 to 53.6) |
For participants that met the criteria for TMA response during the 26-week Treatment Period, loss of TMA response was defined as when the participant failed to meet the criteria for 1 or more components of TMA response at a subsequent visit during the 26-week Treatment Period. At least 1 parameter must have failed to meet the response criteria at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.
| percentage of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Percentage of Participants With Loss of TMA Response During the 26-week Treatment Period | 50.0 (21.1 to 78.9) | 33.3 (7.5 to 70.1) |
This analysis includes data for each participant after achieving TMA response under the composite strategy through Weeks 26 and 52. The criteria for TMA response included a hematological response and a renal response. Time was calculated as the number of days from TMA response under the composite strategy to first loss of response or intercurrent event in the treatment period, or TMA relapse in the follow-up period. Participants must have met each of the response criteria, with each parameter meeting the requirements at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. Participants with TMA response who did not experience these events were censored at their end of study date. The estimate is calculated based on the Kaplan-Meier method. Non-responders were counted as an event with a duration of zero day.
| days | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Duration of TMA Response | 166.0 (29.0 to NA) | NA (38.0 to NA) |
Protocol-specified blood samples were taken for the analysis of haptoglobin in plasma at designated time points. Results are reported as grams/liter (g/L).
| g/L | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26 | 1.111 ± 1.5020 | 1.162 ± 0.8224 |
| Week 52 | 1.172 ± 1.0482 | 0.929 ± 0.5912 |
Protocol-specified blood samples were taken for the analyses of platelets in plasma at designated time points.
| platelets/mm^3 | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26 | 104777.8 ± 85403.27 | 86333.3 ± 95082.01 |
| Week 52 | 153375.0 ± 91605.87 | 130444.4 ± 113473.62 |
Protocol-specified blood samples were taken for the analyses of LDH in plasma at designated time points. Results are reported as units/liter (U/L).
| U/L | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26 | -339.4 ± 315.34 | -334.7 ± 288.12 |
| Week 52 | -428.8 ± 337.68 | -338.6 ± 249.07 |
Protocol-specified blood samples were taken for the analyses of hemoglobin in plasma at designated time points.
| g/dL | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26 | 2.292 ± 2.0607 | 1.689 ± 2.6146 |
| Week 52 | 2.921 ± 2.3478 | 2.711 ± 2.8022 |
The modified criteria for TMA response included a hematological response and a renal response. Hematological Response: if baseline platelet count ≤50000/mm\^3, then the absolute platelet count had to be \>50000/mm\^3 without platelet transfusion support during the prior 7 days; if baseline platelet count \>50000/mm\^3, then there had to be a ≥50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days; at least 50% reduction of LDH from baseline and absence of schistocytes or normalization of LDH and absence of schistocytes. Renal response: at least 50% reduction of proteinuria from baseline. Participants must have met each response criterion, with each parameter meeting the requirement at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.
| percentage of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Percentage of Participants With Modified TMA Response During the 26-week Treatment Period | 21.9 (12.5 to 34.0) | 16.1 (8.0 to 27.7) |
Renal dysfunction was defined as doubling of serum creatinine from baseline or requirement of dialysis. Requirements for dialysis included: at the baseline visit, if there was any dialysis within 5 days prior to the first dose of study treatment; at the post-baseline visit, if there was any dialysis within 5 days prior to the visit. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.
| participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26: Participants experiencing no symptoms at baseline | 18 | 14 |
| Week 26: Participants experiencing symptoms at baseline | 0 | 0 |
| Week 52: Participants experiencing no symptoms at baseline | 21 | 14 |
| Week 52: Participants experiencing symptoms at baseline | 0 | 0 |
Cardiopulmonary dysfunction was defined as the presence of cardiopulmonary symptoms (excluding hypertension) or use of any mechanical ventilation. Cardiopulmonary symptoms included, but were not limited to, pleural effusion, pulmonary edema, pericardial effusion, and serositis. The presence of cardiopulmonary symptoms at baseline and post-baseline visits were assessed and recorded on the electronic case report form (eCRF). Use of any ventilatory or respiratory support, including mechanical ventilation, was reported on the participant's Nonpharmacologic Therapies and Procedures eCRF page. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.
| participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26: Participants experiencing no symptoms at baseline | 10 | 6 |
| Week 26: Participants experiencing symptoms at baseline | 0 | -4 |
| Week 52: Participants experiencing no symptoms at baseline | 10 | 6 |
| Week 52: Participants experiencing symptoms at baseline | 0 | -3 |
Central nervous system dysfunction was defined as confirmed posterior reversible encephalopathy syndrome, or any signs of headache, confusion, visual loss, or seizures at baseline and post-baseline visits, as recorded on the eCRF. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.
| participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26: Participants experiencing no symptoms at baseline | 7 | 11 |
| Week 26: Participants experiencing symptoms at baseline | -2 | -3 |
| Week 52: Participants experiencing no symptoms at baseline | 8 | 11 |
| Week 52: Participants experiencing symptoms at baseline | -2 | -3 |
Gastrointestinal dysfunction was defined as presence of signs and symptoms of gastrointestinal involvement at baseline and post-baseline visits, including diarrhea, vomiting, pain, and bleeding as recorded on the eCRF. Participants categorized as those experiencing no symptoms at baseline and those experiencing symptoms at baseline.
| participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Week 26: Participants experiencing no symptoms at baseline | 20 | 12 |
| Week 26: Participants experiencing symptoms at baseline | -2 | -2 |
| Week 52: Participants experiencing no symptoms at baseline | 20 | 12 |
| Week 52: Participants experiencing symptoms at baseline | -2 | -2 |
For participants that met the criteria for TMA response during the 26-week Treatment Period, TMA relapse was defined as evidence of worsening hematologic and renal dysfunction due to TMA during the post-treatment Follow-up Period and required treatment intervention, as determined by the investigator.
| percentage of participants | Ravulizumab: Stage 2 | Placebo: Stage 2 |
|---|---|---|
| Stage 2: Percentage of Participants With TMA Relapse | 28.6 (3.7 to 71.0) | 0.0 (0 to 41.0) |
Collected over Day 1 through Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ravulizumab: Stage 1 - Treatment Period | 11/20 (55%) | 16/20 (80%) | 17/20 (85%) |
| Ravulizumab: Stage 2 - Treatment Period | 27/63 (42.9%) | 52/63 (82.5%) | 59/63 (93.7%) |
| Placebo: Stage 2 - Treatment Period | 31/62 (50%) | 44/62 (71%) | 54/62 (87.1%) |
| Rescue Ravulizumab: Stage 2 - Treatment Period | 7/10 (70%) | 10/10 (100%) | 9/10 (90%) |
| Ravulizumab: Stage 1 - Follow-up Period | 1/6 (16.7%) | 3/6 (50%) | 4/6 (66.7%) |
| Ravulizumab: Stage 2 - Follow-up Period | 7/34 (20.6%) | 11/34 (32.4%) | 19/34 (55.9%) |
| Placebo: Stage 2 - Follow-up Period | 1/21 (4.8%) | 7/21 (33.3%) | 10/21 (47.6%) |
| Rescue Ravulizumab: Stage 2 - Follow-up Period | 0/3 (0%) | 2/3 (66.7%) | 2/3 (66.7%) |
| Event | Ravulizumab: Stage 1 - Treatment Period | Ravulizumab: Stage 2 - Treatment Period | Placebo: Stage 2 - Treatment Period | Rescue Ravulizumab: Stage 2 - Treatment Period | Ravulizumab: Stage 1 - Follow-up Period | Ravulizumab: Stage 2 - Follow-up Period | Placebo: Stage 2 - Follow-up Period | Rescue Ravulizumab: Stage 2 - Follow-up Period |
|---|---|---|---|---|---|---|---|---|
| Respiratory tract infectionInfections and infestations | 0/20 | 1/63 | 1/62 | 0/10 | 0/6 | 0/34 | 0/21 | 1/3 |
| Facial paralysisNervous system disorders | 0/20 | 0/63 | 0/62 | 0/10 | 0/6 | 0/34 | 0/21 | 1/3 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/20 | 2/63 | 1/62 | 2/10 | 0/6 | 0/34 | 0/21 | 0/3 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/20 | 2/63 | 0/62 | 0/10 | 1/6 | 0/34 | 0/21 | 0/3 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/20 | 2/63 | 0/62 | 0/10 | 1/6 | 0/34 | 0/21 | 0/3 |
| Bacterial infectionInfections and infestations | 0/20 | 0/63 | 0/62 | 0/10 | 1/6 | 0/34 | 0/21 | 0/3 |
| MyelopathyNervous system disorders | 0/20 | 0/63 | 0/62 | 0/10 | 1/6 | 0/34 | 0/21 | 0/3 |
| PneumoniaInfections and infestations | 3/20 | 1/63 | 6/62 | 1/10 | 0/6 | 1/34 | 0/21 | 0/3 |
| Septic shockInfections and infestations | 0/20 | 8/63 | 3/62 | 1/10 | 0/6 | 0/34 | 0/21 | 0/3 |
| Thrombotic microangiopathyBlood and lymphatic system disorders | 2/20 | 3/63 | 3/62 | 1/10 | 0/6 | 0/34 | 0/21 | 0/3 |
| Event | Ravulizumab: Stage 1 - Treatment Period | Ravulizumab: Stage 2 - Treatment Period | Placebo: Stage 2 - Treatment Period | Rescue Ravulizumab: Stage 2 - Treatment Period | Ravulizumab: Stage 1 - Follow-up Period | Ravulizumab: Stage 2 - Follow-up Period | Placebo: Stage 2 - Follow-up Period | Rescue Ravulizumab: Stage 2 - Follow-up Period |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/20 | 3/63 | 6/62 | 0/10 | 3/6 | 0/34 | 0/21 | 0/3 |
| Chronic graft versus host disease in skinImmune system disorders | 1/20 | 3/63 | 1/62 | 0/10 | 0/6 | 0/34 | 0/21 | 1/3 |
| Chronic graft versus host disease oralImmune system disorders | 0/20 | 0/63 | 1/62 | 0/10 | 0/6 | 1/34 | 0/21 | 1/3 |
| Chronic graft versus host disease in eyeImmune system disorders | 0/20 | 0/63 | 0/62 | 0/10 | 0/6 | 0/34 | 1/21 | 1/3 |
| Blood creatinine increasedInvestigations | 1/20 | 2/63 | 5/62 | 0/10 | 0/6 | 0/34 | 0/21 | 1/3 |
| HypokalaemiaMetabolism and nutrition disorders | 3/20 | 11/63 | 16/62 | 2/10 | 0/6 | 2/34 | 2/21 | 1/3 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/20 | 1/63 | 4/62 | 0/10 | 0/6 | 0/34 | 0/21 | 1/3 |
| PyrexiaGeneral disorders and administration site conditions | 3/20 | 19/63 | 12/62 | 0/10 | 0/6 | 2/34 | 3/21 | 0/3 |
| Oedema peripheralGeneral disorders and administration site conditions | 6/20 | 5/63 | 8/62 | 1/10 | 0/6 | 2/34 | 0/21 | 0/3 |
| Cytomegalovirus infection reactivationInfections and infestations | 4/20 | 14/63 | 8/62 | 1/10 | 0/6 | 1/34 | 1/21 | 0/3 |
All Enrolled Participants: all participants who signed the informed consent and were randomized in Stage 2 or were enrolled in Stage 1.
| Age, Customized(participants) | Ravulizumab: Stage 1 | Ravulizumab: Stage 2 | Placebo: Stage 2 | Total |
|---|---|---|---|---|
| 12 to <18 years | 1 | 0 | 2 | 3 |
| 18 to <45 years | 2 | 19 | 20 | 41 |
| 45 to <65 years | 14 | 31 | 25 | 70 |
| ≥65 years | 3 | 14 | 15 | 32 |
| Sex: Female, Male(Participants) | Ravulizumab: Stage 1 | Ravulizumab: Stage 2 | Placebo: Stage 2 | Total |
|---|---|---|---|---|
| Female | 12 | 36 | 38 | 86 |
| Male | 8 | 28 | 24 | 60 |
| Race/Ethnicity, Customized(participants) | Ravulizumab: Stage 1 | Ravulizumab: Stage 2 | Placebo: Stage 2 | Total |
|---|---|---|---|---|
| White | 9 | 36 | 32 | 77 |
| Black or African American | 1 | 3 | 1 | 5 |
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Chinese | 0 | 0 | 4 | 4 |
| Japanese | 8 | 13 | 13 | 34 |
| Korean | 2 | 2 | 0 | 4 |
| Not Reported | 0 | 9 | 9 | 18 |
| Other | 0 | 1 | 1 | 2 |
| More than One Race | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Ravulizumab: Stage 1 | Ravulizumab: Stage 2 | Placebo: Stage 2 | Total |
|---|---|---|---|---|
| Not of Hispanic, Latino/a, or Spanish Origin | 15 | 42 | 40 | 97 |
| Mexican, Mexican American, Chicano/a | 0 | 0 | 1 | 1 |
| Another Hispanic, Latino/a or Spanish Origin | 5 | 11 | 12 | 28 |
| Not Reported | 0 | 10 | 8 | 18 |
| Unknown | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Sep 2025, 57 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Thrombotic Microangiopathies →
Alexion Pharmaceuticals, Inc. →